View Item 

Show simple item record

Review article: defining remission in ulcerative colitis

dc.contributor.authorTravis, S. P. L.en_US
dc.contributor.authorHiggins, Peter D.R.en_US
dc.contributor.authorOrchard, T.en_US
dc.contributor.authorVan Der Woude, C. J.en_US
dc.contributor.authorPanaccione, R.en_US
dc.contributor.authorBitton, A.en_US
dc.contributor.authorO’morain, C.en_US
dc.contributor.authorPanés, J.en_US
dc.contributor.authorSturm, A.en_US
dc.contributor.authorReinisch, W.en_US
dc.contributor.authorKamm, M. A.en_US
dc.contributor.authorD’haens, G.en_US
dc.date.accessioned2011-11-10T15:38:59Z
dc.date.available2012-09-04T15:27:58Zen_US
dc.date.issued2011-07en_US
dc.identifier.citationTravis, S. P. L.; Higgins, P. D. R.; Orchard, T.; Van Der Woude, C. J.; Panaccione, R.; Bitton, A.; O’morain, C. ; Panés, J. ; Sturm, A.; Reinisch, W.; Kamm, M. A.; D’haens, G. (2011). "Review article: defining remission in ulcerative colitis." Alimentary Pharmacology & Therapeutics 34(2). <http://hdl.handle.net/2027.42/87130>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/87130
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleReview article: defining remission in ulcerative colitisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.en_US
dc.contributor.affiliationotherTranslational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK.en_US
dc.contributor.affiliationotherSt Mary’s Hospital, London, UK.en_US
dc.contributor.affiliationotherErasmus MC, Rotterdam, The Netherlands.en_US
dc.contributor.affiliationotherInflammatory Bowel Disease Clinic, University of Calgary, Calgary, AB, Canada.en_US
dc.contributor.affiliationotherMcGill University Health Centre, Montreal, QC, Canada.en_US
dc.contributor.affiliationotherDepartment of Gastroenterology, Adelaide and Meath Hospital and Trinity College, Dublin, Ireland.en_US
dc.contributor.affiliationotherHospital Clínic de Barcelona, IDIBAPS CIBERehd, Barcelona, Spain.en_US
dc.contributor.affiliationotherDivision of Gastroenterology and Hepatology, Charité‐Campus Virchow Clinic, Universitätsmedizin Berlin, Berlin, Germany.en_US
dc.contributor.affiliationotherDepartment of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria.en_US
dc.contributor.affiliationotherSt. Vincent’s Hospital and University of Melbourne, Melbourne, Australia and Imperial College, London, UK.en_US
dc.contributor.affiliationotherDepartment of Gastroenterology, Amsterdam Medical Center, Amsterdam, Netherlands.en_US
dc.identifier.pmid21615435en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/87130/1/j.1365-2036.2011.04701.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2011.04701.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceTravis SPL, Dinesen L. Remission in trials of ulcerative colitis ‐ what does it mean? Pract Gastroenterol 2006; 30: 17 – 20.en_US
dc.identifier.citedreferenceStange EF, Travis SPL, Vermeire S, et al. European evidence‐based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn’s Colitis 2008; 2: 1 – 23.en_US
dc.identifier.citedreferenceCooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials 2007; 8: 17 – 22.en_US
dc.identifier.citedreferenceKatz S. “Mind the Gap”: an unmet need for new therapy in IBD. J Clin Gastroenterol 2007; 41: 799 – 809.en_US
dc.identifier.citedreferenceKatz S, Higgins P, Eusebio R, Yacyshyn B. Different definitions of remission for ulcerative colitis result in large variations of clinical outcome scores. Gastroenterology 2006; 130 ( Suppl. 2 ): A‐482.en_US
dc.identifier.citedreferenceD’Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763 – 86.en_US
dc.identifier.citedreferenceLichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841 – 5.en_US
dc.identifier.citedreferenceTruelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955; 2: 1041 – 8.en_US
dc.identifier.citedreferenceBaron JH, Connell AM, Lennard‐Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964; 1: 89 – 92.en_US
dc.identifier.citedreferencePowell‐Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard‐Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533 – 7.en_US
dc.identifier.citedreferenceSchroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5‐aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625 – 9.en_US
dc.identifier.citedreferenceRutegard I, Ahsgren L, Stenling R, Nilsson T. A simple index for assessment of disease activity in patients with ulcerative colitis. Hepatogastroenterology 1990; 37 ( Suppl. 2 ): 110 – 2.en_US
dc.identifier.citedreferenceRachmilewitz D. Coated mesalazine (5‐aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82 – 6.en_US
dc.identifier.citedreferenceKruis W, Kiudelis G, Rácz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double‐blind, double‐dummy, randomised, non‐inferiority trial. Gut 2009; 58: 233 – 40.en_US
dc.identifier.citedreferenceSutherland LR, Martin F, Greer S, et al. 5‐Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894 – 8.en_US
dc.identifier.citedreferenceMarteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960 – 5.en_US
dc.identifier.citedreferenceHiggins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54: 782 – 8.en_US
dc.identifier.citedreferenceRutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462 – 76.en_US
dc.identifier.citedreferenceSu C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta‐analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007; 132: 516 – 26.en_US
dc.identifier.citedreferenceHanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed‐release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478 – 85.en_US
dc.identifier.citedreferenceKamm MA, Sandborn WJ, Gassull M, et al. Once‐daily, high‐concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66 – 75.en_US
dc.identifier.citedreferenceSinha A, Nightingale J, West KP, Berlanga‐Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild‐to‐moderate left‐sided ulcerative colitis or proctitis. N Engl J Med 2003; 349: 350 – 7.en_US
dc.identifier.citedreferenceHanauer SB, Sandborn WJ, Dallaire C, et al. Delayed‐release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007; 21: 827 – 34.en_US
dc.identifier.citedreferenceWalmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43: 29 – 32.en_US
dc.identifier.citedreferenceColombel JF, Rutgeerts P, Reinisch W, et al. Mucosal healing in patients with ulcerative colitis associates with a reduced colectomy risk, high incidence of symptomatic remission and corticosteroid‐free state. Gut 2010; 59: A411 (Abstract P1511).en_US
dc.identifier.citedreferenceDignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762 – 9.en_US
dc.identifier.citedreferencePaoluzi OA, Iacopini F, Pica R, et al. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1‐year follow‐up study. Aliment Pharmacol Ther 2005; 21: 1111 – 9.en_US
dc.identifier.citedreferenceKamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once‐ or twice‐daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893 – 902.en_US
dc.identifier.citedreferenceKamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild‐to‐moderate ulcerative colitis. Inflamm Bowel Dis 2009; 15: 1 – 8.en_US
dc.identifier.citedreferenceBurger D, Thomas SJ, Walsh AJ, et al. Depth of remission may not predict outcome of ulcerative colitis over 2 years. J Crohn’s Colitis 2011; 5: S4 – 5.en_US
dc.identifier.citedreferenceHiggins P, Schwartz M, Mapili J, Zimmermann EM. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis. Am J Gastroenterol 2005; 100: 355 – 61.en_US
dc.identifier.citedreferenceLanghorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN‐elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162 – 9.en_US
dc.identifier.citedreferenceSeo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971 – 6.en_US
dc.identifier.citedreferenceSeo M, Okada M, Yao T, Okabe N, Maeda K, Oh K. Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts classification. Am J Gastroenterol 1995; 90: 1759 – 63.en_US
dc.identifier.citedreferenceSeo M, Okada M, Maeda K, Oh K. Correlation between endoscopic severity and the clinical activity index in ulcerative colitis. Am J Gastroenterol 1998; 93: 2124 – 9.en_US
dc.identifier.citedreferenceSeo M, Okada M, Yao T, Matake H, Maeda K. Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. J Gastroenterol 2002; 37: 29 – 34.en_US
dc.identifier.citedreferenceBewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2007; 5: 597 – 601.en_US
dc.identifier.citedreferenceLichtenstein GR, Rutgeerts P. The importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010; 16: 338 – 46.en_US
dc.identifier.citedreferenceBernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010; 16: 112 – 24.en_US
dc.identifier.citedreferenceKornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501 – 23.en_US
dc.identifier.citedreferenceCarter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: v1 – 16.en_US
dc.identifier.citedreferenceRutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56: 453 – 5.en_US
dc.identifier.citedreferenceFrøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population‐based cohort. Gastroenterology 2007; 133: 412 – 22.en_US
dc.identifier.citedreferenceEgan LJ, Everett SM, Rutgeerts P. Re‐defining outcomes and re‐evaluating remission in inflammatory bowel disease: assessing key evidence. Biologics 2008; 2 ( Suppl. 1 ): 1 – 14.en_US
dc.identifier.citedreferenceKane S. Endoscopic healing should be a goal for everyone with ulcerative colitis. Inflamm Bowel Dis 2008 [Epub ahead of print].en_US
dc.identifier.citedreferenceRubin DT, Siegel CA, Kane SV, et al. Impact of ulcerative colitis from patients’ and physicians’ perspectives: results from the UC:NORMAL survey. Inflamm Bowel Dis 2009; 15: 581 – 8.en_US
dc.identifier.citedreferenceFeagan BG, Reinisch W, Rutgeerts P, et al. The effects of infliximab therapy on health‐related quality of life in ulcerative colitis patients. Am J Gastrenterol 2007; 102: 794 – 802.en_US
dc.identifier.citedreferenceLakatos L, Lakatos PL. Management of inflammatory bowel diseases in Eastern Europe. Postgrad Med J 2006; 82: 270 – 3.en_US
dc.identifier.citedreferenceRiley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174 – 8.en_US
dc.identifier.citedreferenceBitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13 – 20.en_US
dc.identifier.citedreferenceRubin DT, Huo D, Hetzel JT, et al. Increased degree of histological inflammation predicts colectomy and hospitalisation in patients with ulcerative colitis. Gastroenterology 2007; 132 ( Suppl. 1 ): A‐19 (Abstract 103).en_US
dc.identifier.citedreferenceThomas SJ, Walsh AJ, Von Herbay A, et al. How much agreement is there between histological, endoscopic and clinical assessments of remission in ulcerative colitis. Gut 2009; 58 ( Suppl. 1 ): A101.en_US
dc.identifier.citedreferenceGisbert JP, Bermejo F, Pérez‐Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15: 1190 – 8.en_US
dc.identifier.citedreferenceTibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15 – 22.en_US
dc.identifier.citedreferenceGray JR, Leung E, Scales J. Treatment of ulcerative colitis from the patient’s perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther 2009; 29: 1114 – 20.en_US
dc.identifier.citedreferenceJoyce JC, Waljee AK, Khan T, et al. Identification of symptom domains in ulcerative colitis that occur frequently during flares and are responsive to changes in disease activity. Health Qual Life Outcomes 2008; 6: 69.en_US
dc.identifier.citedreferenceWaljee AK, Joyce JC, Wren PA, Khan TM, Higgins PD. Patient reported symptoms during an ulcerative colitis flare: a Qualitative Focus Group Study. Eur J Gastroenterol Hepatol 2009; 21: 558 – 64.en_US
dc.identifier.citedreferenceKane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39 – 43.en_US
dc.identifier.citedreferenceKane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol The 2006; 23: 577 – 85.en_US
dc.identifier.citedreferenceHawthorne AB, Rubin G, Ghosh S. Review article: medication non‐adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies. Aliment Pharmacol Ther 2008; 27: 1157 – 66.en_US
dc.identifier.citedreferencePrantera C, Rizzi M. 5‐ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol 2009; 15: 4353 – 5.en_US
dc.identifier.citedreferenceChaudhary N, Junior J, Tukey M, Falchuk KR, Cheifetz A, Moss AC. Impact of a patient support program on mesalamine adherence in patients with ulcerative colitis. Gastroenterology 2009; 136 ( S1 ): S1053.en_US
dc.identifier.citedreferenceSaini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22 – 33.en_US
dc.identifier.citedreferenceCross RK, Cheevers N, Finkelstein J. Home telemanagement for patients with ulcerative colitis (UC HAT). Dig Dis Sci 2009; 54: 2463 – 72.en_US
dc.identifier.citedreferenceKane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm 2008; 1 ( Suppl. A ): s2 – 12.en_US
dc.identifier.citedreferenceHiggins PD, Rubin DT, Kaulback K, Schoenfield PS, Kane SV. Systematic review: impact of non‐adherence to 5‐aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther 2009; 29: 247 – 57.en_US
dc.identifier.citedreferenceKripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540 – 50.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2011.04701.x.pdf
Size:
224.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.